Shots:

• The FDA’s De novo clearance is based on five clinical studies in 600+ children diagnosed with ADHD- which demonstrated an improved measure of attention. After 4wks.- one-third of children had no longer measurable attention deficit on at least one measure of objective attention
• Change in child’s day-to-day impairments following @1mos. treatment with EndeavorRx which increased to 68% after 2nd month of treatment. Improvements in ADHD impairments following a month of treatment were maintained for up to a month
• EndeavorRx is indicated for pediatric patients aged 8-12 yrs. with primarily inattentive or combined-type ADHD who have demonstrated an attention issue and will be available with a prescription. The digital therapeutics can be downloaded from the App Store on their mobile devices and does not require any additional equipment

Click here to read full press release/ article | Ref: Akili Therapeutics | Image: Akili Therapeutics